Use of contrast agents in oncological imaging: magnetic resonance imaging

Morana, Giovanni; Cugini, Christian; Scatto, Giuliano; Zanato, Riccardo; Fusaro, Michele; Dorigo, Alberto

doi:10.1102/1470-7330.2013.9018

Cited by 9 publications

(6 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has allowed more accurate tumour detection, characterization and staging. 1 Often, contrast agents are used to improve the MRI. 1,2 These agents most typically contain the paramagnetic gadolinium ion in a chelated form to avoid its potential toxicity.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects

Funck‐Brentano

Felices²,

Fur

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

We investigated the effect of gadopiclenol, a new gadolinium-based contrast agent, on the QTc interval at clinical and supraclinical dose, considering the relative hyperosmolarity of this product. Methods: This was a single centre, randomized, double-blind, placebo-and positivecontrolled, 4-way crossover study. Forty-eight healthy male and female subjects were included to receive single intravenous (i.v.) administrations of gadopiclenol at the clinical dose of 0.1 mmol kg −1 , standard for current gadolinium-based contrast agents, the supraclinical dose of 0.3 mmol kg −1 , placebo and a single oral dose of 400 mg moxifloxacin. Results: The largest time-matched placebo-corrected, mean change from-baseline in QTcF (ΔΔQTcF) was observed 3 hours after administration of 0.1 mmol kg −1 gadopiclenol (2.39 ms, 90% confidence interval [CI]: 0.35, 4.43 ms) and 5 minutes after administration of 0.3 mmol kg −1 (4.81 ms, 90%CI: 2.84, 6.78 ms). The upper limit of the 90% CI was under the threshold of 10 ms, demonstrating no significant effect of gadopiclenol on QTc interval. From 1.5 to 4 hours postdose moxifloxacin, the lower limit of the 90% CI of ΔΔQTcF exceeded 5 ms demonstrating assay sensitivity. Although there was a positive slope, the concentration-response analysis estimated that the values of ΔΔQTcF at the maximal concentration of gadopiclenol at 0.1 and 0.3 mmol kg −1 were 0.41 and 2.23 ms, respectively, with the upper limit of the 90% CI not exceeding 10 ms. No serious or severe adverse events or treatment discontinuations due to adverse events were reported. Conclusion: This thorough QT/QTc study demonstrated that gadopiclenol did not prolong the QT interval at clinical and supraclinical doses and was well tolerated in healthy volunteers. The positive slope of the QTc prolongation vs concentration relationship suggests that hyperosmolarity could be associated with QTc prolongation. However, the amplitude of this effects is unlikely to be associated with proarrhythmia.

show abstract

Section: Introductionmentioning

confidence: 99%

“…Magnetic resonance imaging (MRI) is a widely used technique in the diagnosis of a large number of pathologies but most notably in the field of oncology. It has allowed more accurate tumour detection, characterization and staging 1 . Often, contrast agents are used to improve the MRI 1,2 .…”

Section: Introductionmentioning

confidence: 99%

Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects

Funck‐Brentano

Felices²,

Fur

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Nowadays contrast-enhanced (CE) studies are an essential tool for radiologists, especially for applications in oncology, either when exploiting Gd-based agents within the MRI-CE approach, either upon the administration of iodinated radiographic agents for CT examinations [1][2][3][4][5][6].…”

Section: Introductionmentioning

confidence: 99%

MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent

2016

View full text Add to dashboard Cite

• Gd-based agents are the standard of reference for contrast-enhanced MRI. • Iodinated contrast media provides MRI-CEST contrast enhancement in animal tumour models. • Contrast enhancements were positively correlated between iodinated agents and gadoteridol. • Tumour perfusion map showed similar spatial distribution between iodinated agents and gadoteridol. • MRI-CEST with iodinated agents provide similar information to gadoteridol.

show abstract

“…Meglumine is not internalized inside cells, therefore differences in CEST contrast enhancements are only dependent on the accumulation within the extracellular extravascular space, hence reflecting different vascularization properties. As such, this molecule can be considered an extracellular-fluid agent analogous to the clinically approved Gadolinium-based contrast agents (Morana et al, 2013) or to Iodine-containing X-ray systems (Rutten and Prokop, 2007). Thus, meglumine may be an attractive candidate to be used as MRI-CEST contrast agents for tumor imaging with remarkable contrast efficiency.…”

Section: Discussionmentioning

confidence: 99%

EXCI-CEST: Exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging

Longo

Moustaghfir

Zerbo

et al. 2017

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Chemical Exchange Saturation Transfer (CEST) approach is a novel tool within magnetic resonance imaging (MRI) that allows visualization of molecules possessing exchangeable protons with water. Many molecules, employed as excipients for the formulation of finished drug products, are endowed with hydroxyl, amine or amide protons, thus can be exploitable as MRI-CEST contrast agents. Their high safety profiles allow them to be injected at very high doses. Here we investigated the MRI-CEST properties of several excipients (ascorbic acid, sucrose, N-acetyl-d-glucosamine, meglumine and 2-pyrrolidone) and tested them as tumor-detecting agents in two different murine tumor models (breast and melanoma cancers). All the investigated molecules showed remarkable CEST contrast upon i.v. administration in the range 1-3ppm according to the type of mobile proton groups. A marked increase of CEST contrast was observed in tumor regions up to 30min post injection. The combination of marked tumor contrast enhancement and lack of toxicity make these molecules potential candidates for the diagnosis of tumors within the MRI-CEST approach.

show abstract

Use of contrast agents in oncological imaging: magnetic resonance imaging

Cited by 9 publications

References 44 publications

Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects

Randomized study of the effect of gadopiclenol, a new gadolinium‐based contrast agent, on the QTc interval in healthy subjects

MRI-CEST assessment of tumour perfusion using X-ray iodinated agents: comparison with a conventional Gd-based agent

EXCI-CEST: Exploiting pharmaceutical excipients as MRI-CEST contrast agents for tumor imaging

Contact Info

Product

Resources

About